Overview Request Sample Pages Request Customization Download PDF
You are viewing: North America Preimplantation Genetic Testing Market analysis

The North America Preimplantation Genetic Testing Market was valued at $216.5 Million in 2025 and projected to reach to $350 Million by 2030, representing a compound annual growth rate of 10.1%. North America's preimplantation genetic testing market is positioned for sustained growth through 2030, supported by technological advancements, increasing fertility awareness, and favorable reimbursement policies.

North America Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

North America Preimplantation Genetic Testing Market Trends and Insights

  • In North America, the market is driven by increasing adoption of assisted reproductive technologies, rising awareness of genetic screening benefits, and supportive regulatory frameworks that facilitate innovation.
  • North America's advanced healthcare infrastructure and high fertility treatment costs create strong demand for PGT services among affluent patient populations seeking to reduce genetic disease risks and improve IVF success rates. The North America market benefits from a concentration of leading fertility clinics, diagnostic laboratories, and biotechnology firms investing heavily in PGT capabilities.
  • In North America, technological advancements in next-generation sequencing and array-based testing have reduced costs and turnaround times, making PGT more accessible.
  • Between 2025 and 2030, North America is expected to maintain its position as a premium market, with continued expansion driven by growing consumer demand, insurance coverage improvements, and integration of PGT into standard fertility protocols..

Key Market Statistics

  • CAGR (2025-2030) 10.1% CAGR
  • Market Size, 2025 ~USD 216.5 Million
  • Forecast, 2030 ~USD 350 Million
  • Geography North America

North America Preimplantation Genetic Testing Market Overview

Market Valuation & Growth :

North America's preimplantation genetic testing market is valued at $216.5 million in 2025, with a projected CAGR of 10.1% through 2030, reaching $350.0 million. This robust expansion reflects strong demand for advanced reproductive health solutions across the region.

US Market Dominance :

The United States represents the largest market segment in North America at $320.3 million, driven by high adoption rates of assisted reproductive technologies, advanced healthcare infrastructure, and strong insurance coverage for fertility treatments.

Regulatory & Innovation Support :

North America benefits from supportive regulatory frameworks that facilitate rapid innovation and commercialization of genetic testing technologies. FDA approvals and clear guidelines enable faster market entry for new PGT solutions and methodologies.

Rising Awareness & Adoption :

Increasing consumer awareness of genetic screening benefits, coupled with growing acceptance of assisted reproductive technologies, is driving market expansion. Educational initiatives and improved accessibility are expanding the patient base across North America.

North America Preimplantation Genetic Testing Market Dynamics

  • The region's mature healthcare infrastructure and high disposable income enable widespread adoption of PGT services among fertility clinics and patients seeking advanced reproductive solutions. Key growth drivers include rising maternal age, increasing prevalence of genetic disorders, and expanding insurance coverage for genetic testing.
  • The competitive landscape is intensifying with major diagnostic companies investing in North American markets, while emerging players introduce innovative testing methodologies.
  • Strategic partnerships between fertility centers and genetic laboratories are enhancing service delivery and accessibility across the region..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • North America's PGT market is valued at $216.5 million in 2025 and will reach $350.0 million by 2030, representing a 10.1% CAGR.
      • In North America, advanced healthcare infrastructure and high fertility treatment adoption rates position the region as a leading global PGT market.
      • North America's market growth is fueled by technological innovations in sequencing, improved insurance coverage, and increased consumer awareness of genetic screening benefits.
      • North America maintains premium pricing and high service utilization rates, with fertility clinics increasingly integrating PGT as a standard offering in assisted reproduction protocols.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      North America Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      Target Audience

      • Fertility Clinic Operators : Clinic administrators and medical directors need market data to justify PGT service investments, benchmark against competitors, and understand patient demand trends across North American markets to optimize service offerings.
      • Diagnostic Laboratory Companies : Lab executives require regional market insights to identify expansion opportunities, assess competitive positioning, and develop targeted go-to-market strategies for PGT services in high-growth North American segments.
      • Medical Device & Biotech Investors : Investment firms evaluating reproductive health opportunities need comprehensive North American market data to assess portfolio companies, identify acquisition targets, and evaluate market growth potential and ROI timelines.
      • Healthcare Consultants & Advisors : Consulting firms advising fertility and diagnostic clients require detailed regional market analysis to support strategic planning, market entry strategies, and competitive positioning recommendations across North America.
      • Insurance & Reimbursement Specialists : Payers and reimbursement professionals need market sizing and adoption data to inform coverage policies, pricing negotiations, and budget forecasting for PGT services across North American insurance markets.

      Key Companies in the North America Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      North America vs. other regions

      HowNorth America compares to the other 3 regional blocs covered in this market.

      Europe
      ~USD 211.4 Million · 11.2% wtd CAGR ·
      Asia Pacific
      ~USD 170.3 Million · 12.4% wtd CAGR ·
      Latin America
      ~USD 29.5 Million · 9.4% wtd CAGR ·
      Middle East
      ~USD 14.8 Million · 8.8% wtd CAGR ·

      Countries within North America - compare and drill down

      Country2025 size (native)
      USUSD 320.3 Million
      CanadaUSD 43 Million

      Country market size visualization

      US
      USD 320.3 Million
      Canada
      USD 43 Million

      Reasons to Buy this Report

      • Country-Level Market Breakdown : Access detailed market sizing for US ($320.3M) and Canada ($43M), enabling precise market penetration strategies and regional investment decisions tailored to each North American market's unique characteristics.
      • Growth Trajectory Analysis : Understand the 10.1% CAGR trajectory through 2030, allowing stakeholders to forecast revenue opportunities, plan capacity expansion, and align product development with anticipated market demand in North America.
      • Competitive Positioning Intelligence : Benchmark your organization against regional market dynamics and identify gaps in service delivery. Leverage insights on adoption rates and regulatory environment to refine competitive strategies specific to North American markets.
      • Investment & Partnership Opportunities : Identify high-growth segments and underserved markets within North America. Data supports informed decisions on M&A activities, joint ventures, and strategic partnerships with fertility centers and diagnostic laboratories.
      • Regulatory & Reimbursement Insights : Navigate North America's supportive regulatory landscape and insurance coverage variations. Understand market-specific barriers and enablers to optimize market entry strategies and pricing models across the region.

      Frequently asked questions

      What is the current market size of preimplantation genetic testing in North America?

      In North America, the PGT market was valued at $216.5 million in 2025 and is projected to grow to $350.0 million by 2030.

      What is the expected growth rate for North America's PGT market?

      North America's preimplantation genetic testing market is expected to grow at a compound annual growth rate (CAGR) of 10.1% from 2025 to 2030.

      What factors are driving PGT market growth in North America?

      In North America, key growth drivers include increased adoption of assisted reproductive technologies, rising consumer awareness of genetic screening, technological advancements in sequencing, improved insurance coverage, and integration of PGT into standard fertility protocols.

      How does North America's PGT market compare to other regions?

      North America maintains a premium market position globally, characterized by advanced healthcare infrastructure, high fertility treatment adoption rates, and strong demand for genetic screening services among affluent populations.

      What technological trends are shaping North America's PGT market?

      In North America, next-generation sequencing (NGS) and array-based testing technologies are reducing costs and turnaround times, making PGT more accessible and driving broader adoption across fertility clinics.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status